GEN-1 Immunotherapy Holds Promise for Newly Diagnosed Advanced Ovarian Cancer Patients, Study Says

GEN-1 Immunotherapy Holds Promise for Newly Diagnosed Advanced Ovarian Cancer Patients, Study Says
Combining the DNA-based immunotherapy GEN-1 with neoadjuvant standard-of-care chemotherapy to treat newly-diagnosed advanced ovarian cancer patients who will undergo interval debulking surgery seems to be a promising therapeutic approach, according to data from the OVATION study. Data recently announced by Celsion Corporation showed promising efficacy signals in the first nine patients dosed, including 100% disease control rate, with no dose-limiting toxicities. "While the patient number in this trial may be small, the consistency and robust nature of the data across all three cohorts and the encouraging clinical responses underscore the potential of GEN-1 to serve as an effective, safe IL-12 immunotherapy in ovarian cancer,” Nicholas Borys, MD, Celsion's chief medical officer, said in a press release. “I am particularly impressed with the pathological response data, which is known to be associated with prolonged survival in this patient population. The data generated support continued evaluation of GEN-1 in ovarian cancer, and we look forward to seeing how GEN-1 performs in the fourth and final study cohort.” Celsion's GEN-1 is an IL-12 DNA vector encapsulated by lipid molecules that target tumor cells, allowing for a targeted delivery of IL-12 to the tumor site, and consequent reduction in serious toxicities. The OVATION study (NCT02480374) is a Phase 1b dose-escalating trial meant to assess the safety and ef
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *